Recent Publications

• Trends in cause-specific mortality in HIV-Hepatitis C co-infection following hepatitis C treatment scale-up.
  Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, Gill J, Cooper C, Martel-Laferriere V, Pick N, Klein MB; Canadian Co-Infection Cohort Investigators.
  AIDS. 2019 Jan 12. doi: 10.1097/QAD.0000000000002156.
• Health Care Provider Utilization and Cost of an mHealth Intervention in Vulnerable People Living With HIV in Vancouver, Canada: Prospective Study.
  Campbell AR, Kinvig K, Côté HC, Lester RT, Qiu AQ, Maan EJ, Alimenti A, Pick N, Murray MC.
  JMIR Mhealth Uhealth. 2018 Jul 9;6(7):e152. doi: 10.2196/mhealth.9493.
• Attrition Across the HIV Cascade of Care Among a Diverse Cohort of Women Living With HIV in Canada.
  Kerkerian G, Kestler M, Carter A, Wang L, Kronfli N, Sereda P, Roth E, Milloy MJ, Pick N, Money D, Webster K, Hogg RS, de Pokomandy A, Loutfy M, Kaida A.
  J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):226-236. doi: 10.1097/QAI.0000000000001775.
• The Oak Tree Clinic: The Envisioned Model of Care for Women Living with Human Immunodeficiency Virus in Canada.
  Kestler M, Murray M, Money D, Sauve L, Pick N.
  Womens Health Issues. 2018 Mar – Apr;28(2):197-198. doi: 10.1016/j.whi.2017.11.007. No abstract available.
• Severe menopausal symptoms associated with reduced adherence to antiretroviral therapy among perimenopausal and menopausal women living with HIV in Metro Vancouver.
  Duff PK, Money DM, Ogilvie GS, Ranville F, Kestler M, Braschel MC, Pick N, Shannon K; SHAWNA Project.
  Menopause. 2018 May;25(5):531-537. doi: 10.1097/GME.0000000000001040.
• Contraceptive Choice and Use of Dual Protection Among Women Living with HIV in Canada: Priorities for Integrated Care.
  Kaida A, Patterson S, Carter A, Loutfy M, Ding E, Sereda P, Webster K, Pick N, Kestler M, de Pokomandy A; CHIWOS Research Team.
  Perspect Sex Reprod Health. 2017 Dec;49(4):223-236. doi: 10.1363/psrh.12046. Epub 2017 Nov 29.
• Human Immunodeficiency Virus Viral Load Rebound Near Delivery in Previously Suppressed, Combination Antiretroviral Therapy-Treated Pregnant Women.
  Boucoiran I, Albert AYK, Tulloch K, Wagner EC, Pick N, van Schalkwyk J, Harrigan PR, Money D.
  Obstet Gynecol. 2017 Sep;130(3):497-501. doi: 10.1097/AOG.0000000000002133.
• Access and engagement in HIV care among a national cohort of women living with HIV in Canada.
  Kronfli N, Lacombe-Duncan A, Wang Y, de Pokomandy A, Kaida A, Logie C, Conway T, Kennedy VL, Burchell A, Tharao W, Pick N, Kestler M, Sereda P, Loutfy M, On Behalf Of The Chiwos Research Team.
  AIDS Care. 2017 Oct;29(10):1235-1242. doi: 10.1080/09540121.2017.1338658. Epub 2017 Jun 13.
• Mobile Text Messaging to Improve Medication Adherence and Viral Load in a Vulnerable Canadian Population Living With Human Immunodeficiency Virus: A Repeated Measures Study.
  King E, Kinvig K, Steif J, Qiu AQ, Maan EJ, Albert AY, Pick N, Alimenti A, Kestler MH, Money DM, Lester RT, Murray MCM.
  J Med Internet Res. 2017 Jun 1;19(6):e190. doi: 10.2196/jmir.6631.
• The adherence gap: a longitudinal examination of men’s and women’s antiretroviral therapy adherence in British Columbia, 2000-2014.
  Puskas CM, Kaida A, Miller CL, Zhang W, Yip B, Pick N, Montaner JS, Hogg RS.
  AIDS. 2017 Mar 27;31(6):827-833. doi: 10.1097/QAD.0000000000001408.
• Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV.
  Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, Martel-Laferriere V, Conway B, Pick N, Vachon ML, Klein MB; Canadian Co-infection Cohort Investigators.
  Clin Infect Dis. 2017 May 1;64(9):1154-1162. doi: 10.1093/cid/cix126.
• Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease.
  Maruyama A, Hussaini T, Partovi N, Erb SR, Azalgara VM, Zalunardo N, Pick N, Hull M, Yoshida EM.
  Can J Infect Dis Med Microbiol. 2016;2016:8372835. doi: 10.1155/2016/8372835. Epub 2016 Mar 30.
• Emery J, Pick N, Mills EJ, Cooper CL. Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviral-treated HIV-HCV coinfected patients. Patient Prefer Adherence. 2010 May 13;4:97-103.
• Miller C, McMullin B, Ghaffari A, Stenzler A, Pick N, Roscoe D, Ghahary A, Road J, Av-Gay Y. Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. Nitric Oxide. 2009 Feb;20(1):16-23.
• Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, Cote P, Cox J, Gill J, Haase D, Haider S, Montaner J, Pick N, rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. Cohort Profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study. Int J Epidemiol 2009 Sept, in press.
• Pick N, Rawat M, Arad D, Lan J, Fan J, Kende AS, Av-Gay Y. In vitro properties of antimicrobial bromotyrosine alkaloids. J Med Microbiol 2006 Apr;55 (Pt 4) 407-15.